{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:32:32Z","timestamp":1785335552500,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA108633"],"award-info":[{"award-number":["R01CA108633"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180822"],"award-info":[{"award-number":["U10CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA169368"],"award-info":[{"award-number":["R01CA169368"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA196067"],"award-info":[{"award-number":["U24CA196067"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180850-01"],"award-info":[{"award-number":["U10CA180850-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RC2CA148190"],"award-info":[{"award-number":["RC2CA148190"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005513","name":"Brain Tumor Funders' Collaborative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijrobp.2025.03.043","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T01:38:32Z","timestamp":1743298712000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive Molecular Analysis in NRG Oncology\/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU\/CCNU in Anaplastic Astrocytoma"],"prefix":"10.1016","volume":"123","author":[{"given":"Jessica L.","family":"Fleming","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline P.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D.","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn Stuart","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant K.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Bahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Puduvalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Ian","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Werner-Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-8721","authenticated-orcid":false,"given":"Arnab","family":"Chakravarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.03.043_bib0001","unstructured":"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5463834\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0002","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0003","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0004","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0005","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/29955793\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0006","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/34589661\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0007","first-page":"1529","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0008","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1158\/1078-0432.CCR-13-1157","article-title":"MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951","volume":"19","author":"van den Bent","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0009","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/30259105\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/neuonc\/noz200","article-title":"Survival of diffuse astrocytic glioma, IDH1\/2 wildtype, with molecular features of glioblastoma, WHO grade IV: A confirmation of the cIMPACT-NOW criteria","volume":"22","author":"Tesileanu","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0011","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/32706640\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0012","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00401-012-1016-2","article-title":"MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status","volume":"124","author":"Bady","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0013","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/25760964\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0014","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1093\/nar\/gkr407","article-title":"Predicting the functional impact of protein mutations: Application to cancer genomics","volume":"39","author":"Reva","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0015","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/31996992\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","article-title":"Novel, improved grading system(s) for IDH-mutant astrocytic gliomas","volume":"136","author":"Shirahata","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0017","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00401-017-1690-1","article-title":"Adult infiltrating gliomas with WHO 2016 integrated diagnosis: Additional prognostic roles of ATRX and TERT","volume":"133","author":"Pekmezci","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0018","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40478-017-0465-1","article-title":"The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas","volume":"5","author":"Lee","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0019","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/neuonc\/nox078","article-title":"Adult IDH wild-type lower-grade gliomas should be further stratified","volume":"19","author":"Aibaidula","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0020","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","article-title":"NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide","volume":"27","author":"Wick","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0021","first-page":"95","article-title":"Significance of TERT and ATRX mutations in glioma","volume":"17","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0022","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0023","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00401-013-1156-z","article-title":"ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis","volume":"126","author":"Wiestler","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0024","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/23071247\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0026","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1200\/JCO.2013.49.3726","article-title":"Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH","volume":"32","author":"Cairncross","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/EDBK_238353","article-title":"Management for different glioma subtypes: Are all low-grade gliomas created equal?","volume":"39","author":"Tom","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0028","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/31701682\/"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000534","article-title":"How I treat anaplastic glioma without 1p\/19q codeletion","volume":"4","author":"Berghoff","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0030","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): Second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0031","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3892\/ijo.2015.3026","article-title":"Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)","volume":"47","author":"Cabrini","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.043_bib0032","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1038\/s41467-020-17717-0","article-title":"MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas","volume":"11","author":"Oldrini","year":"2020","journal-title":"Nat Commun"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625002846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625002846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:37:44Z","timestamp":1777955864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625002846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0360301625002846"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.043","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Molecular Analysis in NRG Oncology\/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU\/CCNU in Anaplastic Astrocytoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}